Open Nav

Please submit your session questions in advance at http://bit.ly/BIOCEO19question

Paul Lammers

President and Chief Executive Officer

Triumvira Immunologics

Dr. Paul Lammers joined Triumvira Immunologics as President and Chief Executive Officer on January 1, 2018. In August 2017, he successfully completed a reverse merger of Mirna Therapeutics, the company for whom he served as Director, President, and CEO since 2009, with Synlogic of Cambridge, MA. During his tenure at Mirna Therapeutics, Dr. Lammers raised approximately $160 million in funding, both from Federal and State grants and leading traditional and strategic venture firms. He also brought the company public on the NASDAQ exchange. Previously, Dr. Lammers briefly served as President of Repros Therapeutics (NASDAQ: RPRX) in The Woodlands, Texas. Before Repros Therapeutics, he served 6 years as Chief Medical Officer and Head of US Product Development for EMD Serono Inc., a subsidiary of the German Pharmaceutical company, Merck KgA. Throughout his 30 years in the pharmaceutical and biotech industry, Dr. Lammers held different executive and senior management positions in clinical development, medical affairs, and regulatory affairs at both medium and large pharmaceutical companies, as well as at small public and privately held biotech companies. He started his pharmaceutical career at Organon in the Netherlands, after obtaining both a biology and medical degree, and moved with his family to the US in 1992. Dr. Lammers is a former member of the Board of the New England Healthcare Institute (NEHI) and former Chairman of the Board of BioSymposia, an accredited provider of CME programs for medical scientists and healthcare professionals. He currently serves on ImmunoMet’s Board of Directors.

Back